Thrivent Financial for Lutherans Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Thrivent Financial for Lutherans purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 104,764 shares of the biopharmaceutical company’s stock, valued at approximately $2,450,000. Thrivent Financial for Lutherans owned about 0.07% of TG Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in TGTX. Opaleye Management Inc. increased its position in shares of TG Therapeutics by 2.9% in the first quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after purchasing an additional 65,000 shares during the period. Marshall Wace LLP acquired a new position in shares of TG Therapeutics in the second quarter worth approximately $36,501,000. Hood River Capital Management LLC lifted its stake in shares of TG Therapeutics by 6.7% in the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after acquiring an additional 98,892 shares during the period. Principal Financial Group Inc. lifted its stake in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in TG Therapeutics in the second quarter worth approximately $10,423,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 2.2 %

NASDAQ TGTX opened at $35.00 on Thursday. TG Therapeutics, Inc. has a fifty-two week low of $12.32 and a fifty-two week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a 50 day simple moving average of $26.00 and a two-hundred day simple moving average of $21.95. The stock has a market cap of $5.45 billion, a P/E ratio of -349.97 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TGTX shares. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday. TD Cowen began coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright increased their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.